See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

Summary by MedPage Today
(MedPage Today) -- TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, researchers said here. Continued...

3 Articles

MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

(MedPage Today) -- TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, researchers said here. Continued...

·New York, United States
Read Full Article
neurologylive.comneurologylive.com

IHL-42X Performs in Phase 2 RePOSA Study, ATH434 Eyes Phase 3 Multiple System Atrophy Trial, 4-Year Data on Lecanemab Unveiled

Neurology News Network. for the week ending August 2, 2025. [WATCH TIME: 4 minutes]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Saturday, August 2, 2025.
Sources are mostly out of (0)

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

Alzheimer's Disease icon

Alzheimer's Disease

Toronto, ON icon

Toronto, ON

News
For You
SearchBlindspotLocal